Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics (NASDAQ: RNAC) has granted inducement awards to five new employees on February 3, 2025. The awards consist of options to purchase a total of 168,360 shares of company common stock at an exercise price of $19.89 per share, matching the closing price on Nasdaq Global Market on the grant date.
The options were issued under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and received board approval. The vesting schedule includes 25% vesting on February 3, 2026, followed by three equal annual installments, achieving full vesting by February 3, 2029. The options have a ten-year term and were granted under Nasdaq Listing Rule 5635(c)(4).
Cartesian Therapeutics (NASDAQ: RNAC) ha concesso premi di incentivo a cinque nuovi dipendenti il 3 febbraio 2025. I premi consistono in opzioni per acquistare un totale di 168.360 azioni di azioni ordinarie della società a un prezzo di esercizio di $19,89 per azione, corrispondente al prezzo di chiusura del Nasdaq Global Market alla data di concessione.
Le opzioni sono state emesse nell'ambito del Piano di Incentivi per l'Occupazione Ampliato e Ripristinato 2018 della Società e hanno ricevuto l'approvazione del consiglio. Il piano di vesting prevede il 25% di vesting il 3 febbraio 2026, seguito da tre rate annuali uguali, raggiungendo il vesting completo entro il 3 febbraio 2029. Le opzioni hanno un termine di dieci anni e sono state concesse ai sensi della Regola di quotazione Nasdaq 5635(c)(4).
Cartesian Therapeutics (NASDAQ: RNAC) ha otorgado premios de incentivo a cinco nuevos empleados el 3 de febrero de 2025. Los premios consisten en opciones para comprar un total de 168,360 acciones de acciones ordinarias de la compañía a un precio de ejercicio de $19.89 por acción, igual al precio de cierre en Nasdaq Global Market en la fecha de concesión.
Las opciones se emitieron bajo el Plan de Incentivos de Empleo Modificado y Restablecido de 2018 de la Compañía y recibieron la aprobación de la junta. El calendario de adquisición incluye un 25% de adquisición el 3 de febrero de 2026, seguido de tres cuotas anuales iguales, alcanzando la adquisición completa para el 3 de febrero de 2029. Las opciones tienen un plazo de diez años y se otorgaron bajo la Regla de listado de Nasdaq 5635(c)(4).
Cartesian Therapeutics (NASDAQ: RNAC)는 2025년 2월 3일 다섯 명의 새로운 직원에게 유인 보상을 지급했습니다. 이 보상은 회사 보통주 168,360주를 주당 $19.89에 구매할 수 있는 옵션으로 구성되어 있으며, 이는 보상 날짜에 Nasdaq Global Market에서의 종가와 일치합니다.
옵션은 회사의 수정 및 재시행된 2018년 고용 유인 인센티브 상금 계획 아래 발행되었으며, 이사회 승인을 받았습니다. 배정 일정은 2026년 2월 3일에 25%가 배정되며, 이후 세 개의 동일한 연간 할부가 있으며, 2029년 2월 3일까지 완전 배정에 도달합니다. 이 옵션은 10년의 기간을 가지며 Nasdaq 상장 규칙 5635(c)(4) 아래에서 부여되었습니다.
Cartesian Therapeutics (NASDAQ: RNAC) a attribué des primes d'incitation à cinq nouveaux employés le 3 février 2025. Les primes se composent d'options d'achat totalisant 168 360 actions ordinaires de la société à un prix d'exercice de 19,89 $ par action, correspondant au prix de clôture sur le Nasdaq Global Market à la date de l'attribution.
Les options ont été émises dans le cadre du Plan de primes d'incitation à l'emploi de 2018, modifié et rétabli, de la Société et ont reçu l'approbation du conseil d'administration. Le calendrier d'acquisition prévoit un vesting de 25 % le 3 février 2026, suivi de trois versements annuels égaux, atteignant un vesting complet d'ici le 3 février 2029. Les options ont une durée de dix ans et ont été accordées en vertu de la Règle de cotation Nasdaq 5635(c)(4).
Cartesian Therapeutics (NASDAQ: RNAC) hat am 3. Februar 2025 Anreizvergütungen an fünf neue Mitarbeiter gewährt. Die Vergütungen bestehen aus Optionen zum Kauf von insgesamt 168.360 Aktien des Unternehmens zu einem Ausübungspreis von $19,89 pro Aktie, was dem Schlusskurs am Nasdaq Global Market am Tag der Gewährung entspricht.
Die Optionen wurden im Rahmen des geänderten und neu gefassten 2018 Employee Inducement Incentive Award Plans des Unternehmens ausgegeben und erhielten die Genehmigung des Vorstands. Der Vesting-Zeitplan umfasst eine 25%ige Vesting am 3. Februar 2026, gefolgt von drei gleichen jährlichen Raten, sodass das vollständige Vesting bis zum 3. Februar 2029 erreicht wird. Die Optionen haben eine Laufzeit von zehn Jahren und wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
- None.
- None.
FREDERICK, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On February 3, 2025, the Company issued to these employees options to purchase an aggregate of 168,360 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
How many shares are included in Cartesian Therapeutics (RNAC) February 2025 employee inducement grants?
What is the exercise price for RNAC's February 2025 inducement stock options?
What is the vesting schedule for RNAC's February 2025 inducement stock options?
How long is the term of RNAC's February 2025 inducement stock options?
